Johnson & Johnson-owned Janssen has secured an injunction against drug maker Juno Pharmaceuticals, halting the release of Juno’s generic version of schizophrenia drug Invega Sustenna.
For information on rights and reprints, contact subscriptions@lawyerly.com.au